This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bullous Diseases  • Pemphigoid  • Drug Therapy  • Drug Therapy, Other  • Immunologic Disorders  • Alert me on articles by topic

Petra Kjellman, MD, PhD; Hanna Eriksson, MD; Peter Berg, MD, PhD

Arch Dermatol. 2008;144(5):612-616.

Objectives  To evaluate treatment with methotrexate in patients with bullous pemphigoid and to elucidate the reduced adverse effects compared with standard treatment with prednisone.

Design  Retrospective study (January 1, 1999-December 31, 2003).

Setting  The Department of Dermatology and Venerology, Karolinska University Hospital.

Patients  A total of 138 consecutive patients with bullous pemphigoid were included and were grouped according to the treatment they received: methotrexate, prednisone, a combination of both, or topical glucocorticoids (for mild disease).

Result  Methotrexate was the most effective treatment, with only a few adverse effects and a tendency toward better survival rates in patients with moderate to severe disease.

Conclusion  Methotrexate is an effective and safe drug and provides an excellent treatment option in patients with bullous pemphigoid.

Author Affiliations: Department of Dermatology and Venerology, Karolinska University Hospital, Solna, and Karolinska Institutet, Stockholm, Sweden.